Taro Pharmaceutical Industries Ltd.
TARO
TARO was delisted on the 21st of June, 2024.
94 hedge funds and large institutions have $336M invested in Taro Pharmaceutical Industries Ltd. in 2018 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 28 increasing their positions, 31 reducing their positions, and 29 closing their positions.
10% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 31
18% less funds holding
Funds holding: 114 → 94 (-20)
21% less capital invested
Capital invested by funds: $424M → $336M (-$88.6M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
62% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$4.75M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$3.58M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.04M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.62M |
| 5 |
Bank of New York Mellon
New York
|
+$2.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
Globeflex Capital
San Diego,
California
|
-$7.12M |
| 2 |
AA
ALPS Advisors
Denver,
Colorado
|
-$6.86M |
| 3 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
-$5.72M |
| 4 |
NIPH
NN Investment Partners Holdings
The Hague,
Netherlands
|
-$5.4M |
| 5 |
Morgan Stanley
New York
|
-$5.38M |
TARO Hedge Fund Activity: Q4 2018 in Review
94 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q4 2018, worth a combined $336M — down 21% from $424M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of TARO and 11 opened new positions — a net loss of 18 holders — while 31 trimmed existing stakes and 28 added.
The largest buyer was Renaissance Technologies, adding an estimated $4.75M. The largest seller was Globeflex Capital, exiting entirely with an estimated $7.12M sold.
- 94 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q4 2018, down from 114 in Q3 2018.
- Funds reported $336M of Taro Pharmaceutical Industries Ltd. stock for Q4 2018, down 21% quarter-over-quarter.
- 11 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q4 2018 and 29 closed out, a net change of -18 holders.
- The largest Taro Pharmaceutical Industries Ltd. buyer in Q4 2018 was Renaissance Technologies, an estimated $4.75M added.
- The largest Taro Pharmaceutical Industries Ltd. seller in Q4 2018 was Globeflex Capital, an estimated $7.12M sold.
Based on aggregated 13F filings for Q4 2018.